TCGA-CV-7411-01A-11R-2081-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.620319635
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.530
- HYPOXIA+0.500
- NOTCH_SIGNALING+0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- TGF_BETA_SIGNALING+0.430
- ESTROGEN_RESPONSE_EARLY+0.420
- APICAL_SURFACE+0.380
- TNFA_SIGNALING_VIA_NFKB+0.380
- P53_PATHWAY+0.370
- UV_RESPONSE_DN+0.340
Top 10 suppressed
- E2F_TARGETS-0.690
- MYC_TARGETS_V2-0.590
- G2M_CHECKPOINT-0.550
- MYC_TARGETS_V1-0.410
- DNA_REPAIR-0.380
- INTERFERON_ALPHA_RESPONSE-0.230
- SPERMATOGENESIS-0.180
- MITOTIC_SPINDLE-0.090
- ALLOGRAFT_REJECTION-0.080
- INTERFERON_GAMMA_RESPONSE-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BA-5557-01A-01R-1514-07 | — | — | 0.887 |
| 2 | SRR12475109 | — | — | 0.887 |
| 3 | SRR2932845 | — | — | 0.871 |
| 4 | TCGA-BH-A0DX-01A-11R-A115-07 | — | A | 0.869 |
| 5 | SRR8518353 | — | F | 0.868 |
| 6 | TCGA-A2-A0EO-01A-11R-A034-07 | — | A | 0.865 |
| 7 | SRR8613813 | — | D | 0.865 |
| 8 | TCGA-BH-A0HI-01A-11R-A084-07 | — | B | 0.863 |
| 9 | C3N-04173 | — | cohortA2 | 0.862 |
| 10 | 20060059.TNBC | — | F | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.530 | Remibrutinib | — uncovered |
| HYPOXIA | 0.500 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.460 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.430 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.420 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.380 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.370 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.320 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.300 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.290 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.270 | Inavolisib | — uncovered |